- |||||||||| 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Journal, Metastases: A pilot study on the safety and efficacy of neoadjuvant chemo?adoptive immunotherapy for locally advanced rectal cancer. (Pubmed Central) - Feb 1, 2024
T cells, and mFOLFOX6 every 2 weeks for six courses, followed by surgery 4-6 weeks thereafter...Verification of the efficacy of comprehensive immune cell therapy, especially the induction of antitumor immunity for the prevention of recurrence, will be maintained. The current study is registered with the Japan Registry of Clinical Trials (jRCT; ID, jRCTc030190248; January 21, 2019).
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Retrospective data, Journal: Outcome evaluation of ECF, DCF, FOLFOX, and FLOT chemotherapy regimens as perioperative treatment in elderly patients with resectable gastric cancer; A retrospective comparative study. (Pubmed Central) - Jan 31, 2024
The DCF and FOLFOX regimens accounted for the highest and lowest rates of adverse events (e.g., neutropenia and mucositis), respectively. Considering the higher rate of adverse events in the DCF group, besides the significant improvement of OS and the acceptable adverse event profile of patients treated with the FLOT regimen, it can be proposed that this chemotherapy regimen is the most appropriate treatment option for elderly patients with resectable gastric cancer.
- |||||||||| methotrexate / Generic mfg.
Review, Journal: Delayed low-dose methotrexate excretion in a rheumatoid arthritis patient: A case report and literature review. (Pubmed Central) - Jan 30, 2024
Considering the higher rate of adverse events in the DCF group, besides the significant improvement of OS and the acceptable adverse event profile of patients treated with the FLOT regimen, it can be proposed that this chemotherapy regimen is the most appropriate treatment option for elderly patients with resectable gastric cancer. To ensure rational administration of methotrexate, it is important to fully evaluate the clinical manifestations and physical condition of patients and regularly detecting the serum drug concentration of methotrexate when patients with multiple risk factors, Otherwise, even low-dose methotrexate administration may cause delayed excretion, resulting in severe adverse reactions.
- |||||||||| spevatamig (PT886) / Phanes Therap
Phase classification, Trial completion date, Trial primary completion date, Checkpoint inhibition: Spevatamig (PT886) for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the TWINPEAK Study) (clinicaltrials.gov) - Jan 29, 2024
P1/2, N=72, Recruiting,
To ensure rational administration of methotrexate, it is important to fully evaluate the clinical manifestations and physical condition of patients and regularly detecting the serum drug concentration of methotrexate when patients with multiple risk factors, Otherwise, even low-dose methotrexate administration may cause delayed excretion, resulting in severe adverse reactions. Phase classification: P1 --> P1/2 | Trial completion date: Apr 2024 --> Apr 2026 | Trial primary completion date: Nov 2023 --> Dec 2025
- |||||||||| Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Trial primary completion date, Combination therapy, Metastases: CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Jan 28, 2024
P1/2, N=49, Active, not recruiting,
Trial completion date: Aug 2024 --> Mar 2025 | Trial primary completion date: Aug 2024 --> Mar 2025 Trial primary completion date: Oct 2023 --> Sep 2024
- |||||||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Biomarker, Retrospective data, Journal, Metastases: Genetic Polymorphisms and Tumoral Mutational Profiles over Survival in Advanced Colorectal Cancer Patients: An Exploratory Study. (Pubmed Central) - Jan 26, 2024
Additionally, findings from the genomics of drug sensitivity (GDSC) project demonstrated that cell lines with wild-type BRAF have higher IC50 values for 5-FU compared to BRAF-mutated cell lines. In conclusion, the genetic polymorphisms DPYDrs1801265, ABCB1rs1045642, and MTHFRrs180113 may serve as useful biomarkers for predicting a poor prognosis in patients undergoing 5-fluorouracil chemotherapy, regardless of oncogene mutations.
- |||||||||| oxaliplatin / Generic mfg.
Journal: Three Cases of Febrile Reactions after Using Oxaliplatin (Pubmed Central) - Jan 26, 2024
after 15 h. Although no DLST test was performed in any of the patients, we considered this to be an adverse reaction to OX, owing to lack of symptoms of chills or fever with 5-FU plus l-LV therapy except for OX. The patient should be treated with the knowledge that hypersensitivity reactions to OX do not occur only during the course of administration of OX.
- |||||||||| leucovorin calcium / Generic mfg.
Observational data, Journal: Survival outcomes of patients with stage III colorectal cancer aged???80 (Pubmed Central) - Jan 26, 2024
The patient should be treated with the knowledge that hypersensitivity reactions to OX do not occur only during the course of administration of OX. Completion of adjuvant chemotherapy may improve the prognosis of patients with colorectal cancer aged???80 years, although the number of patients who would benefit from it is limited.
- |||||||||| 5-fluorouracil / Generic mfg.
TWO CARDIOTOXICITIES FROM ONE DOSE OF CHEMOTHERAPY? (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_6726;
This was then followed by PMVT less than 24 hours later. This case highlights the variable clinical presentations of FOLFOX-related cardiotoxicities.
- |||||||||| 5-fluorouracil / Generic mfg.
5-FU MEDIATED CORONARY VASOSPASM LEADING TO STRESS CARDIOMYOPATHY (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_4926;
The mechanism by which 5-FU causes cardiotoxicity is not well defined, but there are several proposed mechanisms including vasospasm, direct myocardial injury, vascular endothelial dysfunction, and impaired oxygen delivery. Patients who are re-challenged with 5-FU have a very high risk of cardiotoxicity recurrence, and mortality can be as high as 10%.
- |||||||||| 5-fluorouracil / Generic mfg.
SEVERE MULTIVESSEL CORONARY VASOSPASM SECONDARY TO 5-FLUOROURACIL MIMICKING ST-SEGMENT-ELEVATION MYOCARDIAL INFARCTION (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_1719;
He had a prior history of cecal carcinoma which was being treated with a chemotherapeutic regimen including leucovorin, 5-FU, and oxaliplatin...The coronary artery vasospasms resolved with the administration of intracoronary nitroglycerine and were presumed secondary to 5-FU... A high index of suspicion is needed in such patient population who already have existing coronary artery disease and can lead to overlapping presentations and delay in cessation of causative agent.
- |||||||||| 5-fluorouracil / Generic mfg.
A CASE OF 5-FLUOROURACIL INDUCED ACUTE HEART FAILURE (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_1373;
5-FU confer benefit to patients with solid tumors however with limited use due to cardiotoxicity. The above case demonstrates the need to further define cardio-protective strategies for patients receiving 5-FU.
- |||||||||| 5-fluorouracil / Generic mfg.
5-FLUOROURACIL INDUCED VASOSPASM AND ACUTE HEART FAILURE (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_1323;
Infusional 5FU regimens are generally preferred over bolus but show equivalent efficacy in terms of disease-free survival for some cancer subcategories. Successful rechallenge is possible with anti-anginal medication, careful monitoring, and multi-disciplinary collaboration.
- |||||||||| 5-fluorouracil / Generic mfg.
UNRAVELING THE ENIGMA OF 5-FLUOROURACIL CARDIOTOXICITY (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_1314;
This case underscores the importance of suspecting 5FU-cardiotoxicity when other causes are excluded and highlights the potential for rapid improvement with cessation. Further research to look at the true incidence of 5FU cardiotoxicity is needed to determine whether the incidence warrants some degree of EF surveillance during treatment.
- |||||||||| 5-fluorouracil / Generic mfg.
A RARE CASE OF 5-FLUOROURACIL INDUCED PERICARDITIS (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_256;
Additionally, the clinician should be vigilant of cardiotoxicity. Monitoring and timely intervention are essential aspects of managing this rare adverse effect.
- |||||||||| Avastin (bevacizumab) / Roche
Journal: Intestinal metastases of colorectal cancer. (Pubmed Central) - Jan 23, 2024
We present the case of an 82-year-old woman with a history of well-differentiated adenocarcinoma of the cecum, stage pT3N1M0, treated ten years before with right hemicolectomy and adjuvant chemotherapy (Capecitabine and Bevacizumab)...Biopsy revealed a moderately differentiated adenocarcinoma with cribriform, nidiform and acinar architectural patterns and positive immunohistochemistry for CK20 and CDX2, compatible with colon origin. The patient was treated with five cycles of chemotherapy (FOLFOX) with the disappearance of the duodenal nodules, although during follow-up she developed disease progression with a left adnexal metastasis with identical histological and immunohistochemical pattern.
- |||||||||| Herceptin (trastuzumab) / Roche, Opdivo (nivolumab) / BMS
Enrollment closed, Enrollment change, HEOR: RENAISSANCE: Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction (clinicaltrials.gov) - Jan 23, 2024
P3, N=183, Active, not recruiting,
The patient was treated with five cycles of chemotherapy (FOLFOX) with the disappearance of the duodenal nodules, although during follow-up she developed disease progression with a left adnexal metastasis with identical histological and immunohistochemical pattern. Recruiting --> Active, not recruiting | N=271 --> 183
- |||||||||| sirexatamab (DKN-01) / Leap Therap
Enrollment closed, Combination therapy, Metastases: DisTinGuish: A Study of DKN-01 in Combination With Tislelizumab (clinicaltrials.gov) - Jan 22, 2024
P2, N=232, Active, not recruiting,
A fast, simple, reliable and cost-efficient extraction and analysis LC-MS method could be developed and validated, which is applicable in ambulatory and clinical care. Recruiting --> Active, not recruiting
- |||||||||| Jelmyto (mitomycin urothelial gel) / UroGen
Trial completion date, Trial primary completion date: PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer (clinicaltrials.gov) - Jan 22, 2024
P1, N=49, Recruiting,
Recruiting --> Active, not recruiting Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
- |||||||||| Zaltrap (ziv-aflibercept IV) / Sanofi
Trial completion: Resection Observatory (clinicaltrials.gov) - Jan 21, 2024
P=N/A, N=140, Completed,
N=288 --> 92 | Recruiting --> Terminated; The study was terminated prematurely due to FUDR production halt in China Active, not recruiting --> Completed
- |||||||||| Avastin (bevacizumab) / Roche
Diagnostic, Management And Neonatal Outcomes Of Pregnancy-Associated Colorectal Cancer: A Case Report And Literature Review. (Poster area) - Jan 18, 2024 - Abstract #ESGO2024ESGO_1001;
Given the favourable response to first-line-chemotherapy, hepatic metastasectomy was performed and twelve cycles of FOLFOX (100%dosage) plus BEVACIZUMAB were administered...We found that women with an early diagnosis were more likely to undergo chemotherapy during pregnancy, resulting in better control of the disease and later WG at-delivery. Chemotherapy during pregnancy is a feasible and safe treatment for PACrC: despite the uncertainties about the effects on the foetus, we did not find different neonatal outcomes between those exposed those who did not.
- |||||||||| Outcomes In Mucinous Ovarian/Fallopian Tube Cancer (MOC); Real World Outcomes From Two Tertiary London Centres (Exhibition hall) - Jan 18, 2024 - Abstract #ESGO2024ESGO_675;
33 patients had systemic anti-cancer therapy (SACT); carboplatin/paclitaxel n=26 (79%); single agent carboplatin n=3 (10%) and FOLFOX/CAPOX n=4 (12%)...We found no benefit from SACT in reducing relapse in early-stage low grade tumours. Patients with advanced stage disease are likely to recur with a short mPFS and mOS reflecting the need for further research to SACT options in this population.
- |||||||||| Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: FBI-TRAC: Trial of Infusional FOLFIRINOX in First Line Treatment of Advanced Biliary Tract Cancers (clinicaltrials.gov) - Jan 17, 2024
P2, N=13, Terminated,
Further research is necessary to establish guidelines for its application. N=32 --> 13 | Trial completion date: Aug 2024 --> Feb 2023 | Recruiting --> Terminated | Trial primary completion date: Aug 2024 --> Feb 2023; poor accrual
|
